AC Immune Announces Upcoming Presentations at AD/PD 2024 - Seite 2

Presenter: Tamara Seredenina, Ph.D. (AC Immune)
Session: FTD, ALS: TDP-43, C9ORF72 and TMEM106B 02
Date/Time: March 8, 2024 at 2:20 – 2:35 pm WET

VacSYn study: An innovative biomarker-based phase 2 clinical trial to evaluate ACI-7104.056, a novel active immunotherapy for Parkinson’s disease
Presenter: Dymitr Kostrica, M.D. (AC Immune)
Session: Advances in PD and LBD drug development
Date/Time: March 9, 2024 at 5:25 – 5:40 pm WET

Poster Presentations
Anti-Abeta liposomal vaccine, ACI-24.060, retains memory in aggressive mouse model of Alzheimer’s disease
Poster number: P0215 / #1422
Presenter: Emma Fiorini, Ph.D. (AC Immune)

Discovery and optimization of novel potent brain penetrant NLRP3 inhibitors
Poster number: P0114 / #1470
Presenter: Tamara Seredenina, Ph.D. (AC Immune)

ACI-7104.056, an active immunotherapy for synucleinopathies, induces a strong and sustained antibody response against alpha-synuclein in non-human primates
Poster number: P0996 / #1513
Presenter: Guenther Staffler, Ph.D. (AC Immune)

About AC Immune SA
AC Immune SA is a clinical-stage biopharmaceutical company and a global leader in precision medicine for neurodegenerative diseases, including Alzheimer’s disease, Parkinson’s disease, and NeuroOrphan indications driven by misfolded proteins. The Company’s two clinically validated technology platforms, SupraAntigen and Morphomer, fuel its broad and diversified pipeline of first- and best-in-class assets, which currently features sixteen therapeutic and diagnostic programs, five of which are currently in Phase 2 clinical trials and one of which is in Phase 3. AC Immune has a strong track record of securing strategic partnerships with leading global pharmaceutical companies, resulting in substantial non-dilutive funding in potential milestone payments plus royalties.

SupraAntigen is a registered trademark of AC Immune SA in the following territories: AU, EU, CH, GB, JP, RU, SG and USA. Morphomer is a registered trademark of AC Immune SA in CN, CH, GB, JP, KR, NO and RU.

The information on our website and any other websites referenced herein is expressly not incorporated by reference into, and does not constitute a part of, this press release.

For further information, please contact:

SVP, Investor Relations & Corporate Communications Gary Waanders, Ph.D., MBA AC Immune Phone: [phone] Email: [e-mail]

U.S. Investors Corey Davis, Ph.D.